Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | o Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Ap |
| 01.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 28.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | cribed in Item 304(a)(1)(v) of Regulation S-K). Item 5.02. Departure of Directors or Certain Officers; Election of Direc |
| 27.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | , and result in a loss of investor confidence. Item 5.02. Departure of Directors or Certain Officers; Election of Dire |
| 03.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointm |
Stammdaten
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Unternehmen & Branche
| Name | Vaxxinity, Inc. |
|---|---|
| Ticker | VAXX |
| CIK | 0001851657 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 12.678 USD |
| Beta | 3,78 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-12-31 | 10-K | -56,934,000 | -0.45 | 44,311,000 | 13,409,000 | |
| 2023-09-30 | 10-Q | -13,145,000 | -0.10 | 57,479,000 | 23,705,000 | |
| 2023-06-30 | 10-Q | -13,977,000 | -0.11 | 71,367,000 | 35,012,000 | |
| 2023-03-31 | 10-Q | -18,421,000 | -0.15 | 85,531,000 | 46,133,000 | |
| 2022-12-31 | 10-K | 0 | -75,222,000 | -0.60 | 106,399,000 | 62,177,000 |
| 2022-09-30 | 10-Q | -19,252,000 | -0.15 | 122,960,000 | 80,261,000 | |
| 2022-06-30 | 10-Q | 50,000 | -17,252,000 | -0.14 | 136,996,000 | 97,341,000 |
| 2022-03-31 | 10-Q | -18,263,000 | -0.15 | 147,528,000 | 112,655,000 | |
| 2021-12-31 | 10-K | 66,000 | -137,175,000 | -1.79 | 166,673,000 | 128,619,000 |
| 2021-09-30 | 10-Q | 50,000 | -30,389,000 | 134,916,000 | -170,920,000 | |
| 2021-06-30 | 10-Q | 17,000 | -26,908,000 | -142,053,000 | ||
| 2021-03-31 | 10-Q | 17,000 | -32,021,000 | -115,849,000 | ||
| 2020-12-31 | 10-K | 557,000 | -39,957,000 | 50,141,000 | -87,375,000 | |
| 2020-09-30 | 10-Q | 117,000 | -16,465,000 | -74,973,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.